Targeted treatment of folate receptor-positive platinum-resistant ovarian cancer and companion diagnostics, with specific focus on vintafolide and etarfolatide

Pharmacogenomics and Personalized Medicine

Volumn 7, Issue 1, 2014, Pages 31-42

  Serpe, Loredana ^a   Gallicchio, Margherita ^a   Canaparo, Roberto ^a   Dosio, Franco ^a  

^a UNIVERSITY OF TURIN   (Italy)

Author keywords

Biomarkers; Etarfolatide; Folate receptor; Platinum resistant ovarian cancer; Targeted therapy; Vintafolide

Indexed keywords

EID: 84893456817     PISSN: None     EISSN: 11787066     Source Type: Journal    
DOI: 10.2147/PGPM.S58374     Document Type: Review

References (88)

1. Siegel R, Naishadham D, Jemal A. Cancer Statistics, 2012. CA Cancer J Clin. 2012;62:10-29.
2. Whittemore AS. Characteristics relating to ovarian cancer risk: implications for prevention and detection. Gynecol Oncol. 1994;55(3 II):S15-S9.
3. Garg PP, Kerlikowske K, Subak L, Grady D. Hormone replacement therapy and the risk of epithelial ovarian carcinoma: a meta-analysis. Obstet Gynecol. 1998;92(3):472-479.
4. Purdie D, Green A, Bain C, et al. Reproductive and other factors and risk of epithelial ovarian cancer: an Australian case-control study. Int J Cancer. 1995;62(6):678-684.
5. Risch HA, Howe GR. Pelvic inflammatory disease and the risk of epithelial ovarian cancer. Cancer Epidemiol Biomarkers Prev. 1995;4(5): 447-451.
6. Schildkraut JM, Schwingl PJ, Bastos E, Evanoff A, Hughes C, Curtin JP. Epithelial ovarian cancer risk among women with polycystic ovary syndrome. Obstet Gynecol. 1996;88(4 Pt 1):554-549.
7. Beral V, Hermon C, Peto R, et al. Ovarian cancer and body size: Individual participant meta-analysis including 25, 157 women with ovarian cancer from 47 epidemiological studies. PLoS Med. 2012;9(4):e1001200.
8. La Vecchia C, Decarli A, Negri E, et al. Dietary factors and the risk of epithelial ovarian cancer. J Natl Cancer Inst. 1987;79(4):663-669.
9. Gilsing AMJ, Weijenberg MP, Goldbohm RA, Van Den Brandt PA, Schouten LJ. Consumption of dietary fat and meat and risk of ovarian cancer in the Netherlands Cohort Study. Am J Clin Nutr. 2011;93(1):118-1126.
10. Hunn J, Rodriguez GC. Ovarian cancer: etiology, risk factors, and epidemiology. Clin Obstet Gynecol. 2012;55(1):3-23.
11. Mackay HJ, Brady MF, Oza AM, et al. Prognostic relevance of uncommon ovarian histology in women with stage III/IV epithelial ovarian cancer. Int J Gynecol Cancer. 2010;20(6):945-952.
12. Omura GA, Brady MF, Homesley HD, et al. Long-term follow-up and prognostic factor analysis in advanced ovarian carcinoma: the Gynecologic Oncology Group experience. J Clin Oncol. 1991;9(7):1138-1150.
13. Fader AN, Rose PG. Role of surgery in ovarian carcinoma. J Clin Oncol. 2007;25(20):2873-2883.
14. Aabo K, Adams M, Adnitt P, et al. Chemotherapy in advanced ovarian cancer: Four systematic meta-analyses of individual patient data from 37 randomized trials. Br J Cancer. 1998;78(11):1479-1487.
15. Ozols RF, Bundy BN, Greer BE, et al; Gynecologic Oncology Group. Phase III trial of carboplatin and paclitaxel compared with cisplatin and paclitaxel in patients with optimally resected stage III ovarian cancer: a Gynecologic Oncology Group study. J Clin Oncol. 2003;21(17):3194-3200.
16. Crane LM, Arts HJ, van Oosten M, et al. The effect of chemotherapy on expression of folate receptor-alpha in ovarian cancer. Cell Oncol. 2012;35(1):9-18.
17. Leamon CP, Lovejoy CD, Nguyen B. Patient selection and targeted treatment in the management of platinum-resistant ovarian cancer. Pharmgenomics Pers Med. 2013;6(1):113-125.
18. Yap TA, Carden CP, Kaye SB. Beyond chemotherapy: targeted therapies in ovarian cancer. Nat Rev Cancer. 2009;9(3):167-181.
19. Naumann RW, Coleman RL. Management strategies for recurrent platinum-resistant ovarian cancer. Drugs. 2011;71(11):1397-1412.
20. Marburger JHI, Kvamme FE. Priorities for Personalized Medicine. 2008; US President's Council of Advisors on Science and Technology. Available from: http://www.whitehouse.gov/files/documents/ostp/PCAST/pcast_report_v2.pdf. Accessed December 19, 2013.
21. Druker BJ, Talpaz M, Resta DJ, et al. Efficacy and safety of a specific inhibitor of the BCR-ABL tyrosine kinase in chronic myeloid leukemia. N Engl J Med. 2001;344(14):1031-1037.
22. Saltz LB, Meropol NJ, Loehrer PJ Sr, Needle MN, Kopit J, Mayer RJ. Phase II trial of cetuximab in patients with refractory colorectal cancer that expresses the epidermal growth factor receptor. J Clin Oncol. 2004;22(7):1201-1208.
23. Cunningham D, Humblet Y, Siena S, et al. Cetuximab monotherapy and cetuximab plus irinotecan in irinotecan-refractory metastatic colorectal cancer. N Engl J Med. 2004;351(4):337-345.
24. Van Cutsem E, Peeters M, Siena S, et al. Open-label phase III trial of panitumumab plus best supportive care compared with best supportive care alone in patients with chemotherapy-refractory metastatic colorectal cancer. J Clin Oncol. 2007;25(13):1658-1664.
25. Spiegelstein O, Eudy JD, Finnell RH. Identification of two putative novel folate receptor genes in humans and mouse. Gene. 2000;258(1-2): 117-125.
26. Saikawa Y. Structural and functional analysis of the human kb cell folate receptor gene P4 promoter: cooperation of three clustered spl-binding sites with initiator region for basal promoter activity. Biochemistry. 1995;34(31):9951-9961.
27. Kamen BA, Wang MT, Streckfuss AJ, Peryea X, Anderson RGW. Delivery of folates to the cytoplasm of MA104 cells is mediated by a surface membrane receptor that recycles. J Biol Chem. 1988;263(27): 13602-13609.
28. Leamon CP, Low PS. Delivery of macromolecules into living cells: a method that exploits folate receptor endocytosis. Proc Natl Acad Sci U S A. 1991;88(13):5572-5576.
29. Turek JJ, Leamon CP, Low PS. Endocytosis of folate-protein conjugates: ultrastructural localization in KB cells. J Cell Sci. 1993;106(1): 423-430.
30. Wu M, Fan J, Gunning W, Ratnam M. Clustering of GPI-anchored folate receptor independent of both cross-linking and association with caveolin. J Membr Biol. 1997;159(2):137-147.
31. Shen F, Ross JF, Wang X, Ratnam M. Identification of a novel folate receptor, a truncated receptor, and receptor type beta in hematopoietic cells: cDNA cloning, expression, immunoreactivity, and tissue specificity. Biochemistry. 1994;33(5):1209-1215.
32. Wang J, Gunning W, Kelley KMM, Ratnam M. Evidence for segregation of heterologous GPI-anchored proteins into separate lipid rafts within the plasma membrane. J Membr Biol. 2002;189(1):35-43.
33. Maziarz KM, Monaco HL, Shen F, Ratnam M. Complete mapping of divergent amino acids responsible for differential ligand binding of folate receptors alpha and beta. J Biol Chem. 1999;274(16):11086-11091.
34. Shen F, Zheng X, Wang J, Ratnam M. Identification of amino acid residues that determine the differential ligand specificities of folate receptors alpha and beta. Biochemistry. 1997;36(20):6157-6163.
35. Elwood PC, Kane MA, Portillo RM, Kolhouse JF. The isolation, characterization, and comparison of the membrane-associated and soluble folate-binding proteins from human KB cells. J Biol Chem. 1986;261(33):15416-15423.
36. Antony AC, Utley CS, Marcell PD, Kolhouse JF. Isolation, characterization, and comparison of the solubilized particulate and soluble folate binding proteins from human milk. J Biol Chem. 1982;257(17):10081-10089.
37. Yang XY, Mackins JY, Li QJ, Antony AC. Isolation and characterization of a folate receptor-directed metalloprotease from human placenta. J Biol Chem. 1996;271(19):11493-11499.
38. Antony AC, Verma RS, Unune AR, LaRosa JA. Identification of a Mg2+-dependent protease in human placenta which cleaves hydrophobic folate-binding proteins to hydrophilic forms. J Biol Chem. 1989;264(4):1911-1914.
39. Luhrs CA, Slomiany BL. A human membrane-associated folate binding protein is anchored by a glycosyl-phosphatidylinositol tail. J Biol Chem. 1989;264(36):21446-21449.
40. Wang J, Shen F, Yan W, Wu M, Ratnam M. Proteolysis of the carboxyl-terminal GPI signal independent of GPI modification as a mechanism for selective protein secretion. Biochemistry. 1997;36(47):14583-14592.
41. Coney LR, Tomassetti A, Carayannopoulos L, et al. Cloning of a tumor-associated antigen: MOv18 and MOv19 antibodies recognize a folate-binding protein. Cancer Res. 1991;51(22):6125-6132.
42. Miotti S, Canevari S, Ménard S, et al. Characterization of human ovarian carcinoma-associated antigens defined by novel monoclonal antibodies with tumor-restricted specificity. Int J Cancer. 1987;39(3):297-303.
43. Chen YL, Chang MC, Huang CY, et al. Serous ovarian carcinoma patients with high alpha-folate receptor had reducing survival and cytotoxic chemo-response. Mol Oncol. 2012;6(3):360-369.
44. Antony AC. Folate receptors. Annu Rev Nutr. 1996;16:501-521.
45. Miotti S, Bagnoli M, Tomassetti A, Colnaghi MI, Canevari S. Interaction of folate receptor with signaling molecules lyn and G alpha(i-3) in detergent-resistant complexes from the ovary carcinoma cell line IGROV1. J Cell Sci. 2000;113(2):349-357
46. Tomassetti A, Mangiarotti F, Mazzi M, et al. The variant hepatocyte nuclear factor 1 activates the P1 promoter of the human beta folate receptor gene in ovarian carcinoma. Cancer Res. 2003;63(3):696-704.
47. Kelemen LE. The role of folate receptor alpha in cancer development, progression and treatment: cause, consequence or innocent bystander? Int J Cancer. 2006;119(2):243-250.
48. Toffoli G, Cernigoi C, Russo A, Gallo A, Bagnoli M, Boiocchi M. Overexpression of folate binding protein in ovarian cancers. Int J Cancer. 1997;74(2):193-198.
49. Toffoli G, Russo A, Gallo A, et al. Expression of folate binding protein as a prognostic factor for response to platinum-containing chemotherapy and survival in human ovarian cancer. Int J Cancer. 1998;79(2): 121-126.
50. Fisher DE. Apoptosis in cancer therapy: crossing the threshold. Cell. 1994;78(4):539-542.
51. Righetti SC, Della Torre G, Pilotti S, et al. A comparative study of p53 gene mutations, protein accumulation, and response to cisplatin-based chemotherapy in advanced ovarian carcinoma. Cancer Res. 1996;56(4): 689-693.
52. Garin-Chesa P, Campbell I, Saigo PE, Lewis JL Jr, Old LJ, Rettig WJ. Trophoblast and ovarian cancer antigen LK26: sensitivity and specificity in immunopathology and molecular identification as a folate-binding protein. Am J Pathol. 1993;142(2):557-567.
53. Zacchetti A, Martin F, Luison E, et al. Antitumor effects of a human dimeric antibody fragment 131I-AFRA-DFM5.3 in a mouse model for ovarian cancer. J Nucl Med. 2011;52(12):1938-1946.
54. Konner JA, Bell-McGuinn KM, Sabbatini P, et al. Farletuzumab, a humanized monoclonal antibody against folate receptor α in epithelial ovarian cancer: a phase I study. Clin Cancer Res. 2010;16(21): 5288-5295.
55. Armstrong DK, White AJ, Weil SC, Phillips M, Coleman RL. Farletuzumab (a monoclonal antibody against folate receptor alpha) in relapsed platinum-sensitive ovarian cancer. Gynecol Oncol. 2013;129(3):452-458.
56. Morphotek. A Safety and efficacy study of farletuzumab in subjects with adenocarcinoma of the lung. Available from: http://clinicaltrials.gov/show/NCT01218516. NLM identifier: NCT01218516. Accessed January 1, 2014.
57. Morphotek. An efficacy and safety study of MORAb-003 in platinum-resistant or refractory relapsed ovarian cancer (FAR-122). Available from: http://clinicaltrials.gov/show/NCT00738699. NLM identifier: NCT00738699. Accessed January 1, 2014.
58. Teng L, Xie J, Teng L, Lee RJ. Clinical translation of folate receptor-targeted therapeutics. Expert Opin Drug Deliv. 2012;9(8):901-908.
59. Leamon CP, Low PS. Folate-mediated targeting: from diagnostics to drug and gene delivery. Drug Discov Today. 2001;6(1):44-51.
60. Leamon CP, Reddy JA. Folate-targeted chemotherapy. Adv Drug Deliv Rev. 2004;56(8):1127-1141.
61. Vlahov IR, Leamon CP. Engineering folate-drug conjugates to target cancer: from chemistry to clinic. Bioconjug Chem. 2012;23(7): 1357-1369.
62. Dosio F, Milla P, Cattel L. EC-145, a folate-targeted vinca alkaloid conjugate for the potential treatment of folate receptor-expressing cancers. Curr Opin Investig Drugs. 2010;11(12):1424-1433.
63. Leamon CP, Parker MA, Vlahov IR, et al. Synthesis and biological evaluation of EC20: a new folate-derived, 99mTc-based radiopharmaceutical. Bioconjug Chem. 2002;13(6):1200-1210.
64. Leamon CP, Reddy JA, Vlahov IR, et al. Comparative preclinical activity of the folate-targeted vinca alkaloid conjugates EC140 and EC145. Int J Cancer. 2007;121(7):1585-1592.
65. Li J, Sausville EA, Klein PJ, et al. Clinical pharmacokinetics and exposure-toxicity relationship of a folate-vinca alkaloid conjugate EC145 in cancer patients. J Clin Pharmacol. 2009;49(12):1467-1476.
66. LoRusso PM, Edelman MJ, Bever SL, et al. Phase I study of folate conjugate EC145 (vintafolide) in patients with refractory solid tumors. J Clin Oncol. 2012;30(32):4011-4016.
67. Siegel BA, Dehdashti F, Mutch DG, et al. Evaluation of 111In-DTPA-folate as a receptor-targeted diagnostic agent for ovarian cancer: initial clinical results. J Nucl Med. 2003;44(5):700-707.
68. Fisher RE, Siegel BA, Edell SL, et al. Exploratory study of 99mTc-EC20 imaging for identifying patients with folate receptor-positive solid tumors. J Nucl Med. 2008;49(6):899-906.
69. Merck Sharp and Dohme Corp. Study of EC145 in patients with advanced ovarian and endometrial cancers. Available from: http://clinicaltrials.gov/show/NCT00507741. NLM identifier: NCT00507741. Accessed January 1, 2014.
70. Lawrie TA, Bryant A, Cameron A, Gray E, Morrison J. Pegylated liposomal doxorubicin for relapsed epithelial ovarian cancer. Cochrane Database Syst Rev. 2013;7:CD006910.
71. Naumann RW, Morris R, Harb W, et al. Protocol EC-FV-02: a phase II study of ec145 in patients with advanced ovarian cancer. Presented at the 16th International Meeting of the European Society of Gynaecological Oncology, Belgrade, Serbia, October 11-14, 2009.
72. Symanowski JT, Maurer AH, Naumann RW, Shah NP, Morgenstern D, Messman RA. Use of 99mTc-EC20 (a folate-targeted imaging agent) to predict response to therapy with EC145 (folate-targeted therapy) in advanced ovarian cancer. J Clin Oncol. 2010;28(Suppl 15):Abstr 5034.
73. Merck Sharp and Dohme Corp. Platinum resistant ovarian cancer evaluation of doxil and EC145 combination therapy (PRECEDENT). Available from: http://clinicaltrials.gov/show/NCT00722592. NLM identifier: NCT00722592. Accessed January 3, 2014.
74. Naumann RW, Symanowski JT, Ghamande SA, et al. PRECEDENT: a randomized phase II trial comparing EC145 and pegylated liposomal doxorubicin (PLD) in combination, versus PLD alone, in subjects with platinum-resistant ovarian cancer. J Clin Oncol. 2010;28(Suppl 18):LBA5012b.
75. Naumann RW, Coleman RL, Burger RA, et al. PRECEDENT: a randomized Phase II trial comparing vintafolide (EC145) and pegylated liposomal doxorubicin (PLD) in combination versus PLD alone in patients with platinum-resistant ovarian cancer. J Clin Oncol. 2013;31(35):4400-4406.
76. Merck Sharp and Dohme Corp. Study for women with platinum resistant ovarian cancer evaluating EC145 in combination with doxil® (PROCEED). Available from: http://clinicaltrials.gov/show/NCT01170650. NLM identifier: NCT01170650. Accessed January 3, 2014.
77. Eisenhauer EA, Therasse P, Bogaerts J, et al. New response evaluation criteria in solid tumours: Revised RECIST guideline (version 1.1). Eur J Cancer. 2009;45:228-247.
78. Naumann RW, Gilbert L, Miller AM, et al. A randomized double-blind phase III trial comparing vintafolide plus pegylated liposomal doxorubicin (PLD) versus PLD plus placebo in patients with platinum-resistant ovarian cancer (PROCEED). J Clin Oncol. 2013;31:TPS5613.
79. Merck Sharp and Dohme Corp. Safety and efficacy study of vintafolide and vintafolide plus paclitaxel compared to paclitaxel alone in participants with Triple Negative Breast Cancer (TNBC) (MK-8109-004). Available from: http://clinicaltrials.gov/show/NCT01953536. NLM identifier: NCT01953536. Accessed January 3, 2014.
80. Merck Sharp and Dohme Corp. A study of MK-8109 (vintafolide) given alone or with chemotherapy in participants with advanced cancers (MK-8109-001). Available from: http://clinicaltrials.gov/show/NCT01688791. NLM identifier: NCT01688791. Accessed January 3, 2014.
81. Chong C, Logothetis C, Savaraj N, Fritsche H, Gietner A, Samuels M. The correlation of vinblastine pharmacokinetics to toxicity in testicular cancer patients. J Clin Pharmacol. 1988;28(8):714-718.
82. Garon EB, Harb WA, Pal SE, et al. EC-FV-03: a phase II study of EC145 (folate-receptor targeted therapy) in patients with advanced lung cancer. J Thorac Oncol. 2009;4 Suppl 1:S452.
83. Markert S, Lassmann S, Gabriel B, et al. Alpha-folate receptor expression in epithelial ovarian carcinoma and non-neoplastic ovarian tissue. Anticancer Res. 2008;28(6A):3567-3572.
84. Wibowo AS, Singh M, Reeder KM, et al. Structures of human folate receptors reveal biological trafficking states and diversity in folate and antifolate recognition. Proc Natl Acad Sci U S A. 2013;110(38): 15180-15188.
85. Walters CL, Arend RC, Armstrong DK, Naumann RW, Alvarez RD. Folate and folate receptor alpha antagonists mechanism of action in ovarian cancer. Gynecol Oncol. 2013;131(2):493-498.
86. van Dam GM, Themelis G, Crane LM, et al. Intraoperative tumor-specific fluorescence imaging in ovarian cancer by folate receptor-α targeting: first in-human results. Nat Med. 2011;17(10):1315-1319.
87. Zajchowski DA, Karlan BY, Shawver LK. Treatment-related protein biomarker expression differs between primary and recurrent ovarian carcinomas. Mol Cancer Ther. 2012;11(2):492-502.
88. Vlahov IR, Santhapuram HK, Wang Y, et al. An assembly concept for the consecutive introduction of unsymmetrical disulfide bonds: synthesis of a releasable multidrug conjugate of folic acid. J Org Chem. 2007;72(16):5968-5972.